WO2002078516A3 - Compositions and methods for the therapy and diagnosis of cancer - Google Patents

Compositions and methods for the therapy and diagnosis of cancer Download PDF

Info

Publication number
WO2002078516A3
WO2002078516A3 PCT/US2002/010421 US0210421W WO02078516A3 WO 2002078516 A3 WO2002078516 A3 WO 2002078516A3 US 0210421 W US0210421 W US 0210421W WO 02078516 A3 WO02078516 A3 WO 02078516A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
polypeptides
cancer
therapy
Prior art date
Application number
PCT/US2002/010421
Other languages
French (fr)
Other versions
WO2002078516A2 (en
Inventor
Tongtong Wang
Siqing Aka Steven Wang
Chaitanya S Bangur
Alexander Gaiger
Original Assignee
Corixa Corp
Tongtong Wang
Siqing Aka Steven Wang
Chaitanya S Bangur
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Tongtong Wang, Siqing Aka Steven Wang, Chaitanya S Bangur, Alexander Gaiger filed Critical Corixa Corp
Priority to AU2002303219A priority Critical patent/AU2002303219A1/en
Publication of WO2002078516A2 publication Critical patent/WO2002078516A2/en
Publication of WO2002078516A3 publication Critical patent/WO2002078516A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly cancers expressing either C-T or C-P antigens, are disclosed. Illustrative compositions comprise one or more tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly cancers expressing either C-T or C-P antigens.
PCT/US2002/010421 2001-03-30 2002-03-28 Compositions and methods for the therapy and diagnosis of cancer WO2002078516A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002303219A AU2002303219A1 (en) 2001-03-30 2002-03-28 Compositions and methods for the therapy and diagnosis of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US28025501P 2001-03-30 2001-03-30
US60/280,255 2001-03-30
US31556301P 2001-08-28 2001-08-28
US60/315,563 2001-08-28
US34731302P 2002-01-09 2002-01-09
US60/347,313 2002-01-09

Publications (2)

Publication Number Publication Date
WO2002078516A2 WO2002078516A2 (en) 2002-10-10
WO2002078516A3 true WO2002078516A3 (en) 2004-03-18

Family

ID=27403126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010421 WO2002078516A2 (en) 2001-03-30 2002-03-28 Compositions and methods for the therapy and diagnosis of cancer

Country Status (2)

Country Link
AU (1) AU2002303219A1 (en)
WO (1) WO2002078516A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
DE10211088A1 (en) 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
AU2012216265B2 (en) * 2002-03-13 2015-01-22 Biontech Ag Genetic products differentially expressed in tumors and use thereof
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003264544A1 (en) * 2002-09-26 2004-04-19 Japan As Represented By President Of National Cancer Center Method of evaluationg canceration degree of mammal-origin specimen
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
EP1755648A2 (en) 2004-05-27 2007-02-28 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
SI1806358T1 (en) * 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
AU2007332819A1 (en) 2006-12-08 2008-06-19 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
EP2918598B1 (en) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP2444503B1 (en) * 2010-10-20 2016-03-02 Université Joseph Fourier Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method
GB201105129D0 (en) 2011-03-28 2011-05-11 Univ Surrey Compositions and methods for treating, diagnosing and monitoring disease
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
US20230057430A1 (en) * 2020-01-13 2023-02-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibition of tap63 regulated oncogenic long non-coding rnas (trolls) in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484726A (en) * 1990-11-21 1996-01-16 Bristol-Myers Squibb Company Antibodies specific for human stromelysin-3 and a method for detection of stromelysin-3
WO1999047669A2 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences from tissue of breast tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484726A (en) * 1990-11-21 1996-01-16 Bristol-Myers Squibb Company Antibodies specific for human stromelysin-3 and a method for detection of stromelysin-3
WO1999047669A2 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences from tissue of breast tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, NATIONAL LIBRARY OF MEDICINE, NIH (BETHESDA, MD, USA); 28 October 1998 (1998-10-28), XP002961247, retrieved from GI:3594650 accession no. NCBI Database accession no. (AI126136) *

Also Published As

Publication number Publication date
AU2002303219A1 (en) 2002-10-15
WO2002078516A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002016413A8 (en) Cripto tumour polypeptide
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP